tbuckley/cabot-search huggingface dataset:
Abstract 17757: Plasma Concentrations of Molecular Lipids are Associated With Coronary Plaque Characteristics and 1-Year Cardiovascular Outcome in Patients With Coronary Artery Disease
Authors: Jin M Cheng, Matti Suoniemi, Isabella Kardys, Terhi Vihervaara, Sanneke De Boer, Martijn Akkerhuis, Marko Sysi-Aho, Kim Ekroos, Hector Garcia-Garcia, Rohit Oemrawsingh, Evelyn Regar, Wolfgang Koenig, Patrick Serruys, Robert-Jan Van Geuns, Eric Boersma, Reijo Laaksonen
Journal: Circulation (2015)

Introduction: Previous lipidomics analyses have demonstrated that several lipid molecules in plasma are associated with fatal outcome in patients with coronary artery disease (CAD). This study aims to investigate the associations of previously identified high risk lipid molecules in plasma with coronary plaque characteristics derived from intravascular ultrasound virtual histology (IVUS-VH) imaging, with coronary lipid core burden index (LCBI) on near-infrared spectroscopy (NIRS), and with one year cardiovascular outcome in patients with CAD. Methods: Between 2008 and 2011, IVUS-VH imaging of a non-culprit coronary artery was performed in 581 patients who underwent coronary angiography for acute coronary syndrome (ACS) or stable CAD. NIRS imaging was additionally performed in 191 patients. Plasma concentrations of molecular lipids were measured with mass spectrometry. Results: Several cholesteryl ester, ceramide and lactosylceramide species and ceramide ratios were associated with vulnerable plaque characteristics on IVUS-VH and NIRS imaging and with 1-year major adverse cardiac events (MACE, defined as all-cause mortality, ACS and unplanned coronary revascularization). In particular, ceramide d18:1/16:0 was consistently associated with higher necrotic core fraction on IVUS-VH (p=0.001), higher LCBI (p=0.024) on NIRS and higher MACE rate (adjusted HR 1.79 per standard deviation increase in log-transformed lipid concentration, 95%CI 1.24-2.59, p=0.002)(Figure). Conclusions: Several molecular lipid species, and particularly ceramide(d18:1/16:0), are associated with the fraction of necrotic core tissue and lipid core burden in coronary atherosclerosis, and are predictive for 1-year clinical outcome after coronary angiography. These molecular lipids may improve risk stratification in CAD and may also be interesting therapeutic targets for the treatment of atherosclerotic disease.
Fatigue in men with metastatic castration-resistant prostate cancer treated with enzalutamide: data from randomised clinical trials
Authors: S. Chowdhury, N. Shore, F. Saad, C.S. Higano, K. Fizazi, P. Iversen, K. Miller, A. Heidenreich, T. Ueda, C.S. Kim, D. Phung, A. Krivoshik, F. Wang, K. Wu, B. Tombal
Journal: Annals of Oncology (2016)
Pregnancy Outcomes among Patients with Chronic Myeloid Leukemia Treated with Dasatinib
Authors: Jorge Cortes, Susan O’Brien, Patricia Ault, Gautam Borthakur, Elias Jabbour, Brigid Bradley-Garelik, Krisztina Debreczeni, Daniel Yang, David Liu, Hagop Kantarjian
Journal: Blood (2008)
Six month course of peanut OIT leads to suppression of basophil activation which begins to wane within four weeks after OIT is stopped
Authors: Michael D. Kulis, Caitlin M. Burk, Xiaohong Yue, Huamei Zhang, Rishu Guo, Kelly Orgel, Ping Ye, Brian P. Vickery, Edwin Kim, A. Wesley Burks
Journal: Journal of Allergy and Clinical Immunology (2017)
Short Telomeres Before Lenalidomide Treatment Predict Leukemic Progression In Patients with Myelodysplastic Syndrome and Deletion 5q
Authors: Gudrun Göhring, Kathrin Lange, Winfried Hofmann, Kirsten Vang Nielsen, Eva Hellström-Lindberg, Lydia Roy, Michael Morgan, Hans Kreipe, Guntram Büsche, Aristoteles Giagounidis, Brigitte Schlegelberger
Journal: Blood (2010)
Sentinel lymph node biopsy among elderly patients with melanoma.
Authors: Michael S. Sabel, David Kozminski, Kent A. Griffith, Alfred E. Chang, Timothy Johnson, Sandra L. Wong
Journal: Journal of Clinical Oncology (2014)

9088 Background: While SLN biopsy is considered standard of care for melanoma ≥1mm in depth, its use among the elderly population is more controversial. To examine this, we reviewed our experience at the University of Michigan with melanoma patients ≥ 75 years of age. Methods: A prospective database was used to identify 952 melanoma patients ≥ 75 years of age from 1996 to 2011. In addition to clinicopathologic features and recurrence and survival data, co-morbidity data was collected to calculate the Charlson co-morbidity index (CCI). Univariate and multivariate Cox regression analysis was performed to characterize predictors of outcome. Kaplan Meier analysis was used to generate survival curves. Results: Among 553 clinically node negative patients with melanoma ≥1mm in Breslow thickness, 213 had wide excision alone while 340 had excision and SLN biopsy, with 83 (24%) having a positive SLN. Predictors of not performing a SLN biopsy included only older age (p<.0001) and head and neck location (p=.007), but not pathologic features or co-morbidity index. A final multiple variable model predicting SLN involvement included female gender [OR 2.15 (95%CI:1.20-3.85) p=.009], Breslow thickness [OR 1.23 for each 1mm increase (95%CI:1.07-1.42) p=0.004] and satellitosis [OR 4.43 (95%CI 1.61-12.21), p=.004]. Distant disease-specific survival was negatively associated with male gender (OR 1.5 (1.12-2.02), p=.007), increasing age (OR 1.05 per year [1.02-1.08, p<.001]), increasing Breslow thickness (OR 1.07 per year [95% CI 1.01-1.13, p=.013), ulceration (OR 1.51 [95%CI 1.14-2] p=.004), a positive SLN (OR 2.61 [95% CI 1.79-3.82], p<.001) and not having a SLN biopsy (OR 1.72 [1.28-2.33], p<.001). CCI did not predict worse disease-free or melanoma specific survival. Conclusions: Among elderly patients with clinically node negative melanoma ≥1mm, 24% harbor SLN metastases. SLN biopsy was not only strongly prognostic, but WLE + SLN biopsy, compared with WLE alone, was associated with improved distant disease-specific survival and a trend towards improved melanoma-specific survival, even after factoring for age and co-morbidities. If otherwise healthy, SLN biopsy should be strongly considered for this population.
BCR-ABL Fluctuation Analysis in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients with MR 4.5
Authors: Mariana Pinto Pereira, Tito Vanelli, Eduardo Gomes da Silva, André Dias Américo, Mariana M Burin, Tahiane Soares, Lucia Silla, Liane Daudt, Laura Fogliatto
Journal: Blood (2015)
468P Osimertinib in patients with T790M mutation positive advanced non-small cell lung cancer (NSCLC): Korean subgroup analysis from pooled phase II data
Authors: M.-J. Ahn, J.-S. Lee, J.-Y. Han, D.-W. Kim, B.C. Cho, J.H. Kang, S.-W. Kim
Journal: Annals of Oncology (2016)
A pooled data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL): Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in non-Hodgkin lymphoma (NHL)
Authors: R.M. Santi, M. Ceccarelli, C. Monagheddu, A. Evangelista, E. Bernocco, F. Monaco, M. Federico, U. Vitolo, S. Cortellazzo, M.G. Cabras, M. Spina, L. Baldini, C. Boccomini, A. Chiappella, A. Bari, S. Luminari, C. Visco, L. Contino, G. Ciccone, M. Ladetto
Journal: Annals of Oncology (2016)
Effect of bisphosphonates (Bis) combined with sunitinib (Su) on the response rate (RR), progression-free survival (PFS), and overall survival (OS) of patients (pts) with bone metastases (mets) from renal cell carcinoma (RCC).
Authors: Daniel Keizman, Maya Ish-Shalom, Jason David Taksey, Roberto Pili, Hans J. Hammers, Mario A. Eisenberger, Ben Boursi, Raanan Berger, Natalie Maimon, Maya Gottfried, Henry Hayat, Avivit Peer, Svetlana Kovel, Avishay Sella, Michael Anthony Carducci
Journal: Journal of Clinical Oncology (2012)

379 Background: Bis are used to prevent skeletal events of bone mets, and may exhibit anti tumor effects. We aimed to evaluate whether Bis can bring a RR, PFS, and OS benefit to pts with bone mets from RCC that are treated with Su. Methods: We performed a multicentre retrospective study of pts with bone mets from RCC who were treated with Su. Pts were divided into Bis users (group 1) and nonusers (group 2). The effect of Bis on RR, PFS and OS, was tested with adjustment for known prognostic factors using a chisquare test from contingency table and partial likelihood test from Cox regression model. Results: Between 2004–2011, 209 pts with metastatic RCC were treated with Su. 76 pts had bone mets, 35 group 1 and 41 group 2. The groups were balanced regarding the following known prognostic factors: past nephrectomy, clear cell/non clear cell histology, time from initial diagnosis to sunitinib treatment (tx), the presence of &gt; 2 mets sites, the presence of lung/liver mets, ECOG performance status, anemia, calcium level &gt;10 mg/dL, elevated alkaline phosphatase, platelets count, pre-tx neutrophil to lymphocyte ratio (NLR) &gt;3, sunitinib induced HTN, and the use of angiotensin system inhibitors. They were also balanced with regard to past cytokines/targeted tx, and mean sunitinib dose/cycle. Objective response was partial response/stable disease 86% (n=30) vs 71% (n=29), and progressive disease 14% (n=5) vs 29% (n=12) (p=0.125, OR 2.48) in group 1 vs 2 respectively. Median PFS was 15 vs 5 months (HR 2.6, p &lt; 0.0001), and median OS 21 vs 13 months (HR 2.1, p=0.029), in favor of group 1. In multivariate analysis of the entire pt cohort (n=76), factors associated with PFS were Bis use (HR 2.2, p=0.035) and pre-tx NLR &gt;3 (HR 0.38, p=0.009). Factors associated with OS were Bis use (HR 2.8, p=0.008), elevated alkaline phosphatase level (HR 0.287, p=0.0003), and Su induced HTN (HR 5.57, p &lt; 0.0001). Conclusions: Bis may improve the outcome of Su tx in RCC with bone mets. Whether this is generalizable to other TKIs is not known. This should be investigated prospectively, and if validated applied in clinical practice and clinical trials.
Effects of Long Term Imatinib on Bone Mineral Density In Patients with Chronic Myelogenous Leukemia (CML) or Gastrointestinal Stromal Tumor (GIST)
Authors: Ellin Berman, Robert Maki, Azeez Farooki, Monica Girotra, Suzanne Chanel, Catherine Cheng, H. William Strauss, Martin Fleisher
Journal: Blood (2010)
The Asthma Adherence Pathway (AAP) Improves Adherence As Well As Asthma Control
Authors: Andrew G. Weinstein, Deborah A. Gentile, Anil Singh, Jennifer Maiolo, David P. Skoner, Allison Kong, Tajpreet Lamba, Rihab Sharara, Keit Ma, Erica Butler
Journal: Journal of Allergy and Clinical Immunology (2017)
Pharmakokinetics of Valganciclovir after AlloSCT: A Fixed Oral Dose Can Be Used for Preemptive Therapy in Patients with Normal Body Weight - Even with Intestinal GVHD.
Authors: Hermann Einsele, Pierre Reusser, Holger Hebart, Bernd Hertenstein, Martin Bornhaeuser, Gerhard Ehninger, Nikolaus Kroeger, Peter Kahls, Yves Chalandon, Frank Rohde
Journal: Blood (2004)
Neoadjuvant erlotinib, erlotinib-sulindac, or placebo: A randomized, double-blind biomarker modulation study in operable head and neck squamous cell carcinoma (HNSCC).
Authors: Julie E. Bauman, Neil D. Gross, William E. Gooding, William Denq, Sufi M. Thomas, Lin Wang, Simion I. Chiosea, Brian L Hood, Melanie S Flint, Mai Sun, Thomas P. Conrads, Robert L. Ferris, Jonas Talmadge Johnson, Seungwon Kim, Athanassios Argiris, Lori J. Wirth, Jill Siegfried, Jennifer R. Grandis
Journal: Journal of Clinical Oncology (2013)

6051 Background: The epidermal growth factor receptor (EGFR) and cyclooxygenase-2 (COX-2) pathways are upregulated in HNSCC. Crosstalk potentiates growth, proliferation and invasion. Preclinical models show synergistic anti-tumor effects from dual blockade. We evaluated biomarker modulation in paired tumor specimens from a 3-arm phase 0 trial of erlotinib, a small molecule EGFR inhibitor; erlotinib + sulindac, a non-selective COX inhibitor; vs. placebo. Methods: Patients (pts) with untreated stage II-IVb HNSCC were randomized 5:5:3 to neoadjuvant erlotinib 150 mg daily (Arm 1, n = 19), erlotinib + sulindac 150 mg twice daily (Arm 2, n = 16), or placebo (n = 12). Pts were treated for 7-14 days. Tumor specimens were collected pre- and post-treatment. The primary endpoint was change in Ki-67 proliferative index. We hypothesized an ordering in Ki-67 down-modulation, with Arm 2 &gt; Arm 1 &gt; placebo. A Jonckheere-Terpstra test evaluated trend; a Wilcoxon test was applied to pairwise contrasts. We prepared tissue microarrays for IHC, to explore pharmacodynamic modulation of 21 EGFR and COX-2 pathway constituents including EGFR, Src, STAT3, Akt, EP2 and EP4. Results: From Dec 2005 – Dec 2008, 48 pts enrolled; 28 tumor pairs were evaluable for biomarker modulation. Class toxicities of EGFR inhibition, including acneiform rash and diarrhea, were observed on Arms 1 and 2. Compared to placebo, Ki-67 was reduced by erlotinib (p = 0.0005) or by erlotinib-sulindac (p = 0.0001). There was a trend in ordering of Ki-67 down-modulation, with greater effect from the addition of sulindac (exact Jonckeheere-Terpstra, Arm 1 vs. 2, p = 0.003). Among 21 protein candidates tested for association with Ki-67, only low baseline p-Src correlated with greater Ki-67 reduction in both erlotinib groups (R 2 = 0.312, p = 0.024). Conclusions: Relative to placebo, brief neoadjuvant treatment with erlotinib or erlotinib-sulindac significantly decreased the proliferative index in operable HNSCC. Sulindac enhanced Ki-67 down-modulation. Efficacy studies of dual EGFR-COX inhibition are justified. Baseline p-Src warrants further study as a resistance biomarker for anti-EGFR therapy. Clinical trial information: NCT01515137.
Risk Factors Associated with the Development of Infusion-Related Reactions in Patients with Chronic Lymphocytic Leukaemia Treated with Anti-CD20 Monoclonal Antibodies: Analysis of the CLL11 Study Dataset
Authors: Ciara Louise Freeman, Mark Dixon, Richard Houghton, Kathryn Humphrey, Gunter Fingerle-Rowson, Karl-Anton Kreuzer, Anja Engelke, Michael Hallek, Valentin Goede
Journal: Blood (2014)
CD300a: A New Player in Atopic Dermatitis?
Authors: Laila Karra, Roopesh Singh Gangwar, Tgst Levi, Yael Minai-Fleminger, Nanna Fyhrquist, Vera Leibovic, Dagmar Simon, Francesca Levi-Schaffer
Journal: Journal of Allergy and Clinical Immunology (2017)
Clinical significance of early circulating tumor cells (CTC) changes, analyzed by AdnaTest, in patients (pts) receiving first-line methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy (CT) for metastatic urothelial cancer (UC)
Authors: E. Fina, A. Necchi, P. Giannatempo, M. Colecchia, D. Raggi, M.G. Daidone, V. Cappelletti
Journal: Annals of Oncology (2016)
456P Practical use of osimertinib in Japanese patients with EGFR T790M mutation positive advanced non-small-cell lung cancer
Authors: M. Kotake, H. Murakami, T. Naito, T. Takahashi, H. Kenmotsu, A. Ono, K. Wakuda, K. Nakashima, S. Omori
Journal: Annals of Oncology (2016)
RARE-27. EXTRACRANIAL METASTATIC GLIOBLASTOMA PRESENTING WITH LHERMITTE’S PHENOMENON, TORTICOLLIS AND QUADRIPARESIS
Authors: Michael Ruff, Sean Pittock
Journal: Neuro-Oncology (2016)

Illustrate a case of epidural glioblastoma metastasis to the cervical spine presenting with torticollis, Lhermitte’s phenomenon and myelopathy. Though exceedingly rare, extracranial and extraneural glioblastoma metastases have been reported in the literature. Activating mutations in the BRAF kinase gene (V600E) are present in a minority of glioblastoma patients. This mutation has not previously been associated with extraneural metastasis in glioblastoma. A 20 year old male with a bi-frontal “butterfly” MGMT unmethylated, IDH1/2 wild type, BRAF V600E positive glioblastoma underwent subtotal resection, radiotherapy with concomitant temozolomide, and adjuvant temozolomide and bevacizumab. At baseline post-operatively he was ambulatory and independent. Over 24 hours he developed progressive quadriparesis, and urinary retention. Upon evaluation he described progressive cervicalgia and torticollis and Lhermitte’s phenomenon over the preceding months. Physical examination was significant for rightward torticollis, quadriparesis, sparing the rectum and hyperreflexia with extensor plantar responses. The patient was unable to stand unassisted. There was decreased pinprick sensation in the lower extremities and chest relative to the upper extremities. Inflammatory markers were markedly elevated. Due to concern for cervical epidural abscess, broad spectrum antibiotics were initiated. LP was not performed. Emergent cervical MRI was obtained which revealed a mass lesion compressing the cervical spine at C2-C5. The patient underwent urgent posterior decompression with debulking of the mass. Final pathology was consistent with metastatic glioblastoma. The patient had minimal recovery postoperatively, and continued to have progression of both intracranial and extracranial disease. The patient underwent palliative spinal radiation and was discharged to hospice. He passed six weeks after presentation. Subacute onset of cervicalgia and torticollis with Lhermitte’s phenomenon in a patient with glioblastoma may represent epidural cervical spine metastases. Further studies are needed to clarify the prognostic and treatment differences associated with activating mutations in the BRAF kinase gene (V600E).
Comparison of Cytogenetics and Interphase Fluorescence In Situ Hybridization in Newly Diagnosed Ph+ Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate. A Study by the GIMEMA Working Party on CML. On Behalf of GWP on CML.
Authors: Nicoletta Testoni, Simona Luatti, Chiara Nicci, Elena Montanari, Giulia Marzocchi, Giorgina Specchia, Marco Mancini, Elisabetta Abruzzese, Giovanna Rege-Cambrin, Antonio Cuneo, Simonetta Kerim, Ursula Giussani, Paolo Bernasconi, Cristina Mecucci, Alfonso Zaccaria, Giancarlo Discepoli, Giovanni Martinelli, Gianantonio Rosti, Michele Baccarani
Journal: Blood (2005)
Effect of targeted therapy on circulating tumor cells in patients with metastatic breast cancer.
Authors: Antonio Giordano, Sara E. Barnato, Mario Giuliano, Ricardo H. Alvarez, Massimo Cristofanilli, Gabriel N. Hortobagyi, Vicente Valero, James M. Reuben
Journal: Journal of Clinical Oncology (2012)

3 Background: Detection of ≥ 5 circulating tumor cells (CTCs) per 7.5 mL of blood before starting systemic treatment is a strong and independent predictor of worse progression-free survival (PFS) and overall survival (OS) in metastatic breast cancer (MBC) patients. It has been demonstrated that trastuzumab and bevacizumab can target CTCs in the peripheral blood of patients with breast cancer and modify the predictive value of the CTC count. We investigated time-related clinical trend of CTCs according to types of targeted therapy in MBC patients. Methods: Enumeration of CTCs was performed by the CellSearch technology as standard of care for 162 MBC patients receiving targeted therapy (trastuzumab, lapatinib, or bevacizumab) for MBC. The evaluation of CTCs was performed as follows: baseline CTC value defined as assay taken within 30 days before starting therapy, follow-up CTC value defined as the lowest CTC value after starting therapy. We analyzed the effect of treatments on CTC count by Wilcoxon matched pair test and estimated PFS and OS by Kaplan-Meier curves. Results: After a median follow-up of 26 months, 143 of 162 (88%) showed progression of disease and 96 (59%) had expired. Sixty-two (38%) patients have received treatment with trastuzumab, 31 (19%) patients with lapatinib, and 69 (43%) patients with bevacizumab. Among patients receiving anti-HER2 targeted treatments, trastuzumab and lapatinib, and those receiving bevacizumab, no differences in terms of median PFS and OS were observed between patients with CTCs greater or equal than 5 and less than 5. Analyzing separate anti-HER2 targeted treatments, we found trastuzumab decreased the number of CTCs at follow-up (P = 0.0003), whereas lapatinib did not (P = 0.14). However, bevacizumab also decreased the number of CTCs at follow-up (P &lt; 0.0001). Conclusions: In MBC patients treated with targeted therapies, basal CTC count was not predictive of PFS and OS. Trastuzumab and bevacizumab significantly decreased the number of CTCs after starting treatment. Moreover, measuring CTCs during the follow-up of MBC patients may represent a predictive tool for targeted therapy failure.
The Nephroprotective Effect of Folic Acid—Only a Matter of Homocysteine?—Reply
Authors: Fan Fan Hou, Xin Xu
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
CanStem303C trial: A phase III study of BBI-608 (napabucasin) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic colorectal cancer (mCRC)
Authors: A. Grothey, N. Tebbutt, E. Van Cutsem, J. Taieb, A. Falcone, T. Yoshino, A. Cervantes, L. Borodyansky, C.J. Li
Journal: Annals of Oncology (2016)
521TiP IMpower133: A phase I/III study of atezolizumab (atezo) with carboplatin (carbo) and etoposide as 1L therapy in patients (pts) with extensive-stage SCLC (ES-SCLC)
Authors: T.S.K. Mok, L. Horn, M. Reck, M.L. Johnson, X. Tang, S. Lam, D.S. Shames, D. Waterkamp, A. Lopez-Chavez, A. Sandler, G. Giaccone, S.V. Liu
Journal: Annals of Oncology (2016)
Does Bioaerosol Exposure Increase the Risk of Pediatric Asthma?
Authors: Nadia Thura, Eugene Hershorin, Lourdes Forster, Sumitha Khatri, Naresh Kumar
Journal: Journal of Allergy and Clinical Immunology (2017)

Miami, FL has high levels of year-round bioaerosols in the form of indoor molds and outdoor pollens. Elevated exposure to bioaerosols can sensitize subjects with predisposition for developing allergies and/or asthma, especially those unexposed previously. We hypothesize that migrants, especially those from higher latitudes, are at a greater risk of developing allergies and asthma after migrating to Miami. An online survey designed with Qualtrics software was administered using iPads in two general pediatric clinics at the University of Miami. The survey includes questions on demographics, migration status, past diagnosis and symptoms of asthma or other allergic respiratory disease, medications, and environmental factors such as exposure to secondhand smoke, pets, and other indoor allergen sources. A total of 109 (∼ 70%) of 162 parents/guardians who were approached participated in the survey. Twenty percent (22 of 109) of children had physician-diagnosed asthma, and 31% of children without an asthma diagnosis reported wheezing in the past. Therefore, diagnosed and possible undiagnosed pediatric asthma prevalence was as high as 45%. Among 109 subjects, 11 were migrants. Although the prevalence of physician-diagnosed asthma among migrants and non-migrants was not significantly different, 27% of migrant children (3 of 11) had physician-diagnosed asthma as compared to 20% (19 of 98) of non-migrants. While the small sample size limits the ability to draw certain conclusions, this research provides important findings concerning the sensitization to bioaerosols in the context of migration to Miami and management of pediatric asthma.